trend travel montenegro

Trend travel Montenegro

Turistička agencija Trend Travel osnovana je aprila 2007. godine. Iskustvo nas je poučilo da su visoki profesionalizam i ljubaznost recept za poslovanje koje traje više od jedne decenije.

Sa dvije poslovnice i širokim spektrom usluga, predstavljamo jednu od vodećih turističkih agencija u regionu.

Nalazimo se u srcu starog grada u Herceg Novom, na trgu Herceg Stjepana poznatijeg po imenu Belavista. Zarad lakšeg pristupa našoj agenciji, otvorili smo novu poslovnicu smeštenu u blizini glavne autobuske stanice u Herceg Novom. U gradu obojenom mimozama i okupanom suncem, poslujemo već dugi niz godina.

Uz pomoć našeg tima, spremnog da u svakom momentu odgovori na zahtjeve klijenata, garantujemo da će Vaš foto-album biti pun divnih uspomena kojima ćete se rado vraćati.

Website :  https://trendtravelmontenegro.com/

Telefon :  +382 69 570 027  ;  +382 31 321 639  ;  +382 31 321 244  ;  +382 69 146 853

Najnovija dešavanja

Boka Bay Boat Tour

Teretana "Terzo"

Montenegro Wild Boat

Concord Limousines

Pogledajte fotografiju

Travel & Tourism - Montenegro

• According to projections, the Travel & Tourism market in Montenegro is expected to generate a revenue of US$25.13m by 2024.
• This revenue is expected to grow annually by 2.73%, resulting in a projected market volume of US$28.75m by 2029.
• The largest market in the Montenegrin market is the Package Holidays market, with a projected market volume of US$9.73m in 2024.
• It is expected that the number of users in Package Holidays will amount to 87.17k users by 2029.
• In 2024, the user penetration will be 15.3%, which is expected to increase to 18.1% by 2029.
• The average revenue per user (ARPU) is expected to be US$261.90.
• It is estimated that by 2029, 72% of the total revenue in the Montenegrin Travel & Tourism market will be generated through online sales.
• In comparison to other countries, United States is projected to generate the most revenue, amounting to US$214bn in 2024.
• Montenegro's Travel & Tourism sector is booming, with the country's stunning coastline and mountainous landscape attracting an increasing number of visitors.

Key regions: Malaysia , Europe , Singapore , Vietnam , United States

Definition:

The Travel & Tourism market encompasses a diverse range of accommodation services catering to the needs and preferences of travelers. This dynamic market includes package holidays, hotel accommodations, private vacation rentals, camping experiences, and cruises.

The market consists of five further markets.

• The Cruises market covers multi-day vacation trips on a cruise ship. The Cruises market encompasses exclusively passenger ticket revenues.
• The Vacation Rentals market comprises of private accommodation bookings which includes private holiday homes and houses as well as short-term rental of private rooms or flats.
• The Hotels market includes stays in hotels and professionally run guest houses.
• The Package Holidays market comprises of travel deals that normally contain travel and accommodation sold for one price, although optional further provisions can be included such as catering and tourist services.
• The Camping market includes bookings at camping sites for pitches using tents, campervans, or trailers. These can be associated with big chains or privately managed campsites.

Additional Information:

The main performance indicators of the Travel & Tourism market are revenues, average revenue per user (ARPU), users and user penetration rates. Additionally, online and offline sales channel shares display the distribution of online and offline bookings. The ARPU refers to the average revenue one user generates per year while the revenue represents the total booking volume. Revenues are generated through both online and offline sales channels and include exclusively B2C revenues and users for the above-mentioned markets. Users represent the aggregated number of guests. Each user is only counted once per year. Additional definitions for each market can be found within the respective market pages.

The booking volume includes all booked travels made by users from the selected region, independent of the departure and arrival. The scope includes domestic and outbound travel.

Prominent players in this sector include online travel agencies (OTAs) like Expedia and Opodo, as well as tour operators such as TUI. Specialized platforms like Hotels.com, Booking.com, and Airbnb facilitate the online booking of hotels and private accommodations, contributing significantly to the market's vibrancy.

For further information on the data displayed, refer to the info button right next to each box.

• Bookings directly via the website of the service provider, travel agencies, online travel agencies (OTAs) or telephone

out-of-scope

• Business trips
• Other forms of trips (e.g. excursions, etc.)

Travel & Tourism

• Vacation Rentals
• Package Holidays
• Analyst Opinion

Montenegro, a small country in Southeast Europe, is experiencing significant growth in its Travel & Tourism market. Customer preferences: Travelers in Montenegro are increasingly seeking unique and authentic experiences, moving away from traditional tourist hotspots and exploring off-the-beaten-path destinations. This shift in preferences is driving the development of niche tourism offerings such as eco-tourism, adventure travel, and cultural experiences. Trends in the market: One notable trend in the Montenegrin Travel & Tourism market is the rise of digital nomadism. With the increasing popularity of remote work, many individuals are choosing to live and work in Montenegro for an extended period, blending work with leisure. This trend is driving demand for long-term accommodation options and co-working spaces in the country. Local special circumstances: Montenegro's stunning natural landscapes, including its picturesque coastline along the Adriatic Sea and rugged mountains, serve as a major draw for tourists. The country's rich cultural heritage, with influences from various civilizations, also adds to its appeal. Additionally, Montenegro's relatively affordable prices compared to other European destinations make it an attractive option for budget-conscious travelers. Underlying macroeconomic factors: The growth of the Travel & Tourism market in Montenegro is supported by favorable macroeconomic conditions, including stable economic growth and government initiatives to promote the sector. Investments in infrastructure development, such as the expansion of airports and the improvement of road networks, have also contributed to the growth of the tourism industry in the country. Furthermore, Montenegro's increasing integration into the global economy and efforts to attract foreign direct investment have helped boost the overall competitiveness of its tourism sector.

• Methodology

Data coverage:

Modeling approach:

Additional notes:

• Sales Channels
• Travel Behavior
• Global Comparison
• Key Market Indicators

Mon - Fri, 9am - 6pm (EST)

Mon - Fri, 9am - 5pm (SGT)

Mon - Fri, 10:00am - 6:00pm (JST)

Mon - Fri, 9:30am - 5pm (GMT)

• Get immediate access to all Market Insights, reports & statistics
• Download data in multiple formats for collaborative research
• Includes usage & publication rights for sharing data externally

You are using an outdated browser. Upgrade your browser today or install Google Chrome Frame to better experience this site.

• Section 2 - Interactions Between Travel Vaccines & Drugs
• Section 2 - Travelers’ Diarrhea

Yellow Fever Vaccine & Malaria Prevention Information, by Country

Cdc yellow book 2024.

Author(s): Mark Gershman, Rhett Stoney (Yellow Fever) Holly Biggs, Kathrine Tan (Malaria)

The following pages present country-specific information on yellow fever (YF) vaccine requirements and recommendations, and malaria transmission information and prevention recommendations. Country-specific maps are included to aid in interpreting the information. The information in this chapter was accurate at the time of publication; however, it is subject to change at any time due to changes in disease transmission or, in the case of YF, changing entry requirements for travelers. Updated information reflecting changes since publication can be found in the online version of this book and on the Centers for Disease Control and Prevention (CDC) Travelers’ Health website. Recommendations for prevention of other travel-associated illnesses can also be found on the CDC Travelers’ Health website .

Yellow Fever Vaccine

Entry requirements.

Entry requirements for proof of YF vaccination under the International Health Regulations (IHR) differ from CDC’s YF vaccination recommendations. Under the IHR, countries are permitted to establish YF vaccine entry requirements to prevent the importation and transmission of YF virus within their boundaries. Certain countries require proof of vaccination from travelers arriving from all countries ( Table 5-25 ); some countries require proof of vaccination only for travelers above a certain age coming from countries with risk for YF virus transmission. The World Health Organization (WHO) defines areas with risk for YF virus transmission as countries or areas where YF virus activity has been reported currently or in the past, and where vectors and animal reservoirs exist.

Unless issued a medical waiver by a yellow fever vaccine provider, travelers must comply with entry requirements for proof of vaccination against YF.

WHO publishes a list of YF vaccine country entry requirements and recommendations for international travelers approximately annually. But because entry requirements are subject to change at any time, health care professionals and travelers should refer to the online version of this book and the CDC Travelers’ Health website for any updates before departure.

CDC Recommendations

CDC’s YF vaccine recommendations are guidance intended to protect travelers from acquiring YF virus infections during international travel. These recommendations are based on a classification system for destination-specific risk for YF virus transmission: endemic, transitional, low potential for exposure, and no risk ( Table 2-08 ). CDC recommends YF vaccination for travel to areas classified as having endemic or transitional risk (Maps 5-10 and 5-11 ). Because of changes in YF virus circulation, however, recommendations can change; therefore, before departure, travelers and clinicians should check CDC’s destination pages for up-to-date YF vaccine information.

Duration of Protection

In 2015, the US Advisory Committee on Immunization Practices published a recommendation that 1 dose of YF vaccine provides long-lasting protection and is adequate for most travelers. The recommendation also identifies specific groups of travelers who should receive additional doses, and others for whom additional doses should be considered (see Sec. 5, Part 2, Ch. 26, Yellow Fever ). In July 2016, WHO officially amended the IHR to stipulate that a completed International Certificate of Vaccination or Prophylaxis is valid for the lifetime of the vaccinee, and YF vaccine booster doses are not necessary. Moreover, countries cannot require proof of revaccination (booster) against YF as a condition of entry, even if the traveler’s last vaccination was >10 years ago.

Ultimately, when deciding whether to vaccinate travelers, clinicians should take into account destination-specific risks for YF virus infection, and individual risk factors (e.g., age, immune status) for serious YF vaccine–associated adverse events, in the context of the entry requirements. See Sec. 5, Part 2, Ch. 26, Yellow Fever , for a full discussion of YF disease and vaccination guidance.

Table 2-08 Yellow fever (YF) vaccine recommendation categories 1

Malaria prevention.

The following recommendations to protect travelers from malaria were developed using the best available data from multiple sources. Countries are not required to submit malaria surveillance data to CDC. On an ongoing basis, CDC actively solicits data from multiple sources, including WHO (main and regional offices); national malaria control programs; international organizations; CDC overseas offices; US military; academic, research, and aid organizations; and the published scientific literature. The reliability and accuracy of those data are also assessed.

If the information is available, trends in malaria incidence and other data are considered in the context of malaria control activities within a given country or other mitigating factors (e.g., natural disasters, wars, the coronavirus disease 2019 pandemic) that can affect the ability to control malaria or accurately count and report it. Factors such as the volume of travel to that country and the number of acquired cases reported in the US surveillance system are also examined. In developing its recommendations, CDC considers areas within countries where malaria transmission occurs, substantial occurrences of antimalarial drug resistance, the proportions of species present, and the available malaria prophylaxis options.

Clinicians should use these recommendations in conjunction with an individual risk assessment and consider not only the destination but also the detailed itinerary, including specific cities, types of accommodations, season, and style of travel, as well as special health conditions (e.g., pregnancy). Several medications are available for malaria prophylaxis. When deciding which drug to use, consider the itinerary and length of trip, travelers’ previous adverse reactions to antimalarials, drug allergies, medical history, and drug costs. For a thorough discussion of malaria and guidance for prophylaxis, see Sec. 5, Part 3, Ch. 16, Malaria .

Afghanistan

Entry requirements : None

CDC recommendations : Not recommended

• All areas <2,500 m (≈8,200 ft) elevation (April–December)
• Chloroquine
• P. vivax  (primarily)
• P. falciparum (less commonly)
• Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3

Other Vaccines to Consider

See Health Information for Travelers to Afghanistan

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission 1

No malaria transmission

See Health Information for Travelers to Albania

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

See Health Information for Travelers to Algeria

American Samoa (US)

See Health Information for Travelers to American Samoa

See Health Information for Travelers to Andorra

Entry requirements : Required for arriving travelers  ≥9 months old

CDC recommendations : Recommended for all travelers ≥9 months old

• P. falciparum (primarily)
• P. malariae , P. ovale , and P. vivax (less commonly)

See Health Information for Travelers to Angola

Anguilla (U.K.)

See Health Information for Travelers to Anguilla (U.K.)

See Health Information for Travelers to Antarctica

Antigua and Barbuda

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

See Health Information for Travelers to Antigua and Barbuda

CDC recommendations : Recommended for travelers ≥9 months old going to Corrientes and Misiones Provinces. Generally not recommended for travel to Formosa Province or to designated areas of Chaco, Jujuy, and Salta Provinces. Not recommended for travel limited to provinces and areas not listed above.

Related Maps

Map 2-01 Yellow fever vaccine recommendations for Argentina & neighboring countries

See Health Information for Travelers to Argentina

See Health Information for Travelers to Armenia

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1 Entry will be denied if a valid vaccination certificate cannot be provided.

See Health Information for Travelers to Aruba

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1 Travelers arriving from the Galápagos Islands of Ecuador are exempt from this requirement.

See Health Information for Travelers to Australia

See Health Information for Travelers to Austria

See Health Information for Travelers to Azerbaijan

Azores (Portugal)

See Health Information for Travelers to Azores

Bahamas, The

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

See Health Information for Travelers to The Bahamas

See Health Information for Travelers to Bahrain

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes airport transits or layovers in countries with risk for YF virus transmission. 1

• Districts of Chittagong Hill Tract (Bandarban, Khagrachari, and Rangamati); and the following districts: Chattogram (Chittagong) and Cox’s Bazar (in Chattogram [Chittagong] Division); Mymensingh, Netrakona, and Sherpur (in Mymensingh Division); Kurigram (in Rangpur Division); Habiganj, Moulvibazar, Sunamganj, and Sylhet (in Sylhet Division)
• No malaria transmission in Dhaka (the capital)
• P. falciparum (90%)
• P. vivax (10%)
• P. malariae  (rare)

See Health Information for Travelers to Bangladesh

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission. 1 Travelers arriving from Guyana or Trinidad & Tobago are exempt from this requirement, unless an outbreak is occurring.

See Health Information for Travelers to Barbados

See Health Information for Travelers to Belarus

See Health Information for Travelers to Belgium

• Rare transmission
• No malaria transmission in Belize City or on islands frequented by tourists (e.g., Ambergris Caye)
• P. vivax (primarily)
• None (insect bite precautions / mosquito avoidance only) 4

See Health Information for Travelers to Belize

Entry requirements : Required for all arriving travelers ≥9 months old

• P. falciparum  (primarily)
• P. malariae ,  P. ovale,  and  P. vivax  (less commonly)

See Health Information for Travelers to Benin

Bermuda (U.K.)

See Health Information for Travelers to Bermuda (U.K.)

• Rare cases in rural areas <1,700 m (≈5,500 ft) elevation in districts along the southern border shared with India
• P. falciparum  (less commonly)
• None (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Bhutan

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission. 1

CDC recommendations : Recommended for travelers ≥9 months old going to areas <2,300 m (≈7,550 ft) elevation, east of the Andes Mountains: the entire departments of Beni, Pando, Santa Cruz, and designated areas in the departments of Chuquisaca, Cochabamba, La Paz, and Tarija. Not recommended for travel limited to areas >2,300 m (≈7,550 ft) elevation and any areas not listed above, including the cities of La Paz (administrative capital) and Sucre (constitutional [legislative and judicial] capital).

• All areas <2,500 m (≈8,200 ft) elevation
• No malaria transmission in La Paz (administrative capital)
• P. vivax  (99%)
• P. falciparum  (1%)
• Atovaquone-proguanil, doxycycline, mefloquine, primaquine 5 , tafenoquine 3

Map 2-02. Yellow fever vaccine recommendations for Bolivia & neighboring countries

See Health Information for Travelers to Bolivia

See Health Information for Travelers to Bonaire

Bosnia and Herzegovina

See Health Information for Travelers to Bosnia and Herzegovina

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes transits through countries with risk for YF virus transmission. 1

• Districts/ subdistricts of Bobirwa, Boteti, Chobe (including Chobe National Park), Ghanzi, Mahalapye, Ngamiland (Ngami), North East (including its capital, Francistown), Okavango, Serowe/ Palapye, and Tutume
• Rare cases or sporadic foci of transmission in districts/ subdistricts of Kgalagadi North, Kgatleng, Kweneng, and Southern
• No malaria transmission in Gaborone (the capital)
• P. malariae ,  P. ovale , and  P. vivax  (less commonly)
• Districts/subdistricts of Bobirwa, Boteti, Chobe (including Chobe National Park), Ghanzi, Mahalapye, Ngamiland (Ngami), North-East (including its capital, Francistown), Okavango, Serowe/Palapye, and Tutume: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• Areas with rare cases or sporadic foci of transmission: no chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Botswana

CDC recommendations : Recommended for travelers ≥9 months old going to the states of Acre, Amapá, Amazonas, Distrito Federal (including the capital city, Brasília), Espírito Santo,* Goiás, Maranhão, Mato Grosso, Mato Grosso do Sul, Minas Gerais, Pará, Paraná,* Piauí, Rio de Janeiro (including the city of Rio de Janeiro and all coastal islands),* Rio Grande do Sul,* Rondônia, Roraima, Santa Catarina,* São Paulo (including the city of São Paulo and all coastal islands),* Tocantins, and designated areas of Bahia*. Vaccination is also recommended for travelers going to Iguaçu Falls. Not recommended for travel limited to any areas not listed above, including the cities of Fortaleza and Recife *In 2017, in response to a large YF outbreak in multiple eastern states, CDC expanded its vaccination recommendations for travelers going to Brazil. The expanded YF vaccination recommendations for these states are preliminary. For updates, refer to the CDC Travelers’ Health website.

• All areas in the states of Acre, Amapá, Amazonas, Rondônia, and Roraima
• Present in the states of Maranhão, Mato Grosso, and Pará, but rare cases in their capital cities (São Luis [capital of Maranhão], Cuiabá [capital of Mato Grosso], Belém [capital of Pará])
• Rural and forested areas in the states of Espírito Santo, Goiás, Minas Gerais, Mato Grosso do Sul, Piauí, Rio de Janeiro, São Paolo, and Tocantins
• No malaria transmission in the cities of Brasília (the capital), Rio de Janeiro, or São Paolo
• No malaria transmission at Iguaçu Falls
• P. vivax  (90%)
• P. falciparum  (10%)
• Areas with rare cases: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4
• Map 2-03 Yellow fever vaccine recommendations for Brazil & neighboring countries
• Map 2-04 Malaria prevention in Brazil

See Health Information for Travelers to Brazil

British Indian Ocean Territory; includes Diego Garcia (U.K.)

See Health Information for Travelers to British Indian Ocean Territory (U.K.)

• No human malaria
• Rare transmission of P. knowlesi 6 in primarily forested or forest-fringe areas
• P. knowlesi 6 (100%)
• None (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Brunei

See Health Information for Travelers to Bulgaria

Burkina Faso

Entry requirements : Required for all arriving travelers ≥9 months old

CDC recommendations : Recommended for all travelers ≥9 months old.

• P. malariae ,  P. ovale , and  P. vivax (less commonly)

See Health Information for Travelers to Burkina Faso

Burma (Myanmar)

• All areas <1,000 m (≈3,300 ft) elevation, including Bagan
• Rare transmission in areas >1,000 m (≈3,300 ft) elevation
• Chloroquine and mefloquine
• P. vivax (60%)
• P. falciparum (40%)
• P. knowlesi 6 , P. malariae , and P. ovale (rare)
• Areas <1,000 m (≈3,300 ft) elevation in the regions of Bago and Tanintharyi, and in the states of Kachin, Kayah, Kayin, and Shan: Atovaquone-proguanil, doxycycline, tafenoquine 3
• Areas <1,000 m (≈3,300 ft) elevation in all other areas: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine  3
• Areas >1,000 m (≈3,300 ft) elevation: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only)  4

See Health Information for Travelers to Burma (Myanmar)

Entry requirements : Required for all arriving travelers ≥9 months old.

CDC recommendations : Recommended for all travelers ≥9 months old.

See Health Information for Travelers to Burundi

• Present throughout the country
• No (or negligible) malaria transmission in the cities of Phnom Penh (the capital) and Siem Reap
• No (or negligible) malaria transmission at the main temple complex at Angkor Wat
• P. vivax (80%)
• P. falciparum (20%)
• P. knowlesi 6 (rare)
• Atovaquone-proguanil, doxycycline, tafenoquine 3

See Health Information for Travelers to Cambodia

Entry requirements : Required for all arriving travelers ≥1 year old.

See Health Information for Travelers to Cameroon

See Health Information for Travelers to Canada

Canary Islands ( Spain )

See Health Information for Travelers to Canary Islands (Spain)

• No indigenous cases reported since 2018
• Previously, rare cases on Santiago (São Tiago) Island and Boa Vista Island
• Previously, chloroquine
• Previously, P. falciparum (primarily)

See Health Information for Travelers to Cape Verde

Cayman Islands (U.K.)

See Health Information for Travelers to Cayman Islands (U.K.)

Central African Republic

Entry requirements : Required for all arriving travelers ≥9 months old .

See Health Information for Travelers to Central African Republic

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission. 1

CDC recommendations : Recommended for travelers ≥9 months old going to areas south of the Sahara Desert. Not recommended for travel limited to areas in the Sahara Desert.

See Health Information for Travelers to Chad

See Health Information for Travelers to Chile

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1 Travelers with itineraries limited to Hong Kong Special Administrative Region (SAR) or Macao SAR are exempt from this requirement.

See Health Information for Travelers to China

Christmas Island (Australia)

See Health Information for Travelers to Christmas Island (Australia)

Cocos (Keeling) Islands (Australia)

See Health Information for Travelers to Cocos (Keeling) Islands (Australia)

Entry requirements : Required for travelers ≥1 year old arriving from Angola, Brazil, Democratic Republic of the Congo, or Uganda; this includes >12-hour airport transits or layovers in any of these countries.

CDC recommendations : Recommended for all travelers ≥9 months old except as follows. Generally not recommended for travel limited to the cities of Barranquilla, Cali, Cartagena, or Medellín. Not recommended for travel limited to areas >2,300 m (≈7,550 ft) elevation, the archipelago department of San Andrés and Providencia, or the city of Bogotá (the capital).

• All areas <1,700 m (≈5,600 ft) elevation
• No malaria transmission in the cities of Bogotá (the capital), Cartagena, or Medellín
• P. falciparum  (50%)
• P. vivax  (50%)

Map 2-05 Yellow fever vaccine recommendations for Colombia & neighboring countries

See Health Information for Travelers to Colombia

• P. malariae and P. vivax (rare)

See Health Information for Travelers to Comoros

Congo, Republic of the (Congo-Brazzaville)

Entry requirements : Required for all arriving travelers ≥9 months old.

See Health Information for Travelers to Congo, Republic of the

Cook Islands (New Zealand)

See Health Information for Travelers to Cook Islands (New Zealand)

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission. 1 Included in this requirement are travelers arriving from Tanzania and Zambia, and designated areas of: Colombia (the entire country, except the cities of Barranquilla, Bogotá, Cali, Cartagena, and Medellín, and the archipelago department, San Andrés and Providencia); Ecuador (the provinces of Morona-Santiago, Napo, Orellana, Pastaza, Sucumbíos, and Zamora-Chinchipe, and excluding the rest of the country); Paraguay (the entire country, except the city of Asunción); Peru (the entire country, except the cities of Cusco and Lima, the regions of Cajamarca, Lambayeque, Piura, and Tumbes, and the highland tourist areas of Machu Picchu and the Inca Trail); Trinidad & Tobago (the entire country, except the urban areas of Port of Spain; travelers with itineraries limited to the island of Tobago, and travelers with airport transits or layovers are also exempt from this requirement). Travelers arriving from Argentina and Panama are exempt from this requirement.

• Present in the provinces of Alajuela and Limón
• Rare to no transmission in other parts of the country
• P. falciparum (86%)
• P. vivax (14%)
• Alajuela and Limón Provinces: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, tafenoquine 3
• All other areas: None (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Costa Rica

Côte d'Ivoire (Ivory Coast)

See Health Information for Travelers to Côte d'Ivoire

See Health Information for Travelers to Croatia

See Health Information for Travelers to Cuba

Curaçao, Netherlands

See other recommended vaccines and medicines for travelers to Curaçao

See Health Information for Travelers to Cyprus

See Health Information for Travelers to Czech Republic

Democratic Republic of the Congo (Congo-Kinshasa)

CDC recommendations : Recommended for all travelers ≥9 months old

See Health Information for Travelers to Democratic Republic of the Congo

See Health Information for Travelers to Denmark

• P. falciparum (60–70%)
• P. vivax (30–40%)
• P. ovale (rare)

See Health Information for Travelers to Djibouti

See Health Information for Travelers to Dominica

Dominican Republic

Entry requirements : Required for travelers ≥1 year old arriving from the following states in Brazil: Espírito Santo, Mina Gerais, Rio de Janeiro, São Paulo; this includes >12-hour airport transits or layovers in any of these states

• Primarily in the provinces near the border with Haiti, and the provinces (including resort areas) of La Altagracia, San Cristóbal, San Juan, and Santo Domingo
• In the Distrito Nacional, city of Santo Domingo (the capital), primarily in the La Ciénaga and Los Tres Brazos areas
• Rare transmission in other provinces
• P. falciparum  (100%)
• Provinces near the border with Haiti, and the provinces (including resort areas) of La Altagracia, San Cristóbal, San Juan, and Santo Domingo: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, tafenoquine 3
• All other areas: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Dominican Republic

Easter Island (Chile)

Entry requirements : Easter Island has not stated its YF vaccination certificate requirements

See Health Information for Travelers to Easter Island (Chile) .

Ecuador, including the Galápagos Islands

Entry requirements : Required for travelers ≥1 year old arriving from Brazil, Democratic Republic of the Congo, or Uganda; this includes >12-hour airport transits or layovers in any of these countries .

CDC recommendations : Recommended for travelers ≥9 months old going to areas <2,300 m (≈7,550 ft) elevation, east of the Andes Mountains, in the provinces of Morona-Santiago, Napo, Orellana, Pastaza, Sucumbíos, Tungurahua,* and Zamora-Chinchipe. Generally not recommended for travel limited to areas <2,300 m (≈7,550 ft) elevation, west of the Andes Mountains, in the provinces of Esmeraldas,* Guayas, Los Ríos, Manabí, Santa Elena, Santo Domingo de los Tsáchilas, and designated areas in the provinces of Azuay, Bolívar, Cañar, Carchi, Chimborazo, Cotopaxi, El Oro, Imbabura, Loja, and Pichincha. Not recommended for travel limited to areas >2,300 m (≈7,550 ft) elevation, the cities of Guayaquil or Quito (the capital), or the Galápagos Islands *CDC recommendations differ from those published by WHO .

• Areas <1,500 m (≈5,000 ft) elevation in the provinces of Carchi, Cotopaxi, Esmeraldas, Morona-Santiago, Orellana, Pastaza, and Sucumbíos
• Rare cases <1,500 m (≈5,000 ft) in all other provinces
• No malaria transmission in the cities of Guayaquil or Quito (the capital)
• No malaria transmission on the Galápagos Islands
• P. vivax  (85%)
• P. falciparum  (15%)
• Transmission areas in the provinces of Carchi, Cotopaxi, Esmeraldas, Morona-Santiago, Orellana, Pastaza, and Sucumbíos: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• All other areas with reported malaria transmission: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

Map 2-06 Yellow fever vaccine recommendations for Ecuador & neighboring countries

See Health Information for Travelers to Ecuador .

See Health Information for Travelers to Egypt .

El Salvador

See Health Information for Travelers to El Salvador .

Equatorial Guinea

• P. malariae, P. ovale , and P. vivax  (less commonly)

See Health Information for Travelers to Equatorial Guinea .

CDC recommendations : Generally not recommended for travel to the regions of: Anseba, Debub (also known as South or Southern Region), Gash Barka, Ma’ekel (also known as Ma’akel or Central Region), or Semenawi K’eyih Bahri (also known as Northern Red Sea Region). Not recommended for travel to any areas not listed above, including the Dahlak Archipelago.

• All areas <2,200 m (≈7,200 ft) elevation
• No malaria transmission in Asmara (the capital)
• P. falciparum  (80–85%)
• P. vivax (15–20%)
• P. malariae and P. ovale (rare)

Map 5-10 Yellow fever vaccine recommendations for Africa

See Health Information for Travelers to Eritrea .

See Health Information for Travelers to Estonia .

Eswatini (Swaziland)

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission; this includes airport transits or layovers in countries with risk for YF virus transmission. 1

• Eastern areas bordering Mozambique and South Africa, including the entire region of Lubombo and the eastern half of Hhohho, Manzini, and Shiselweni Regions
• P. malariae , P. ovale , and  P. vivax  (less commonly)

See Health Information for Travelers to Swaziland .

CDC recommendations : Recommended for all travelers ≥9 months old except as follows. Generally not recommended for travel limited to the regions of Afar or Somali.

• All areas <2,500 m (≈8,200 ft) elevation, except none in Addis Ababa (the capital)
• P. falciparum  (80%)
• P. vivax  (20%)
• P. malariae and P. ovale  (rare)

Map 2-07 Yellow fever vaccine recommendations for Ethiopia & neighboring countries

See Health Information for Travelers to Ethiopia .

Falkland Islands (Islas Malvinas), UK Overseas Territory (also claimed by Argentina)

See Health Information for Travelers to Falkland Islands (Islas Malvinas) .

Faroe Islands (Denmark)

See Health Information for Travelers to Faroe Islands (Denmark) .

See Health Information for Travelers to Fiji .

See Health Information for Travelers to Finland .

See Health Information for Travelers to France .

French Guiana

• Areas associated with gold mining, primarily the communes near the border with Brazil and Suriname, especially Régina and Saint-Georges-de-l’Oyapock; also, the communes of Kourou, Matoury, and Saint-Élie
• No malaria transmission in coastal areas west of Kourou
• No malaria transmission in Cayenne City (the capital)
• P. falciparum (15%)

See Health Information for Travelers to French Guiana (France) .

French Polynesia, including the Society Islands [Bora-Bora, Moorea & Tahiti]; Marquesas Islands [Hiva Oa & Ua Huka]; and Austral Islands (Tubuai & Rurutu), France

See Health Information for Travelers to French Polynesia (France) .

• P. malariae , P. ovale , and P. vivax  (less commonly)

See Health Information for Travelers to Gabon .

Gambia, The

See Health Information for Travelers to The Gambia .

See Health Information for Travelers to Georgia .

See Health Information for Travelers to Germany .

• P. malariae,   P. ovale, and   P. vivax (less commonly)

See Health Information for Travelers to Ghana .

Gibraltar (U.K.)

See Health Information for Travelers to Gibraltar (U.K.) .

• Rare, local transmission in agricultural areas, associated with imported malaria (May–November)
• No malaria transmission in tourist areas
• Not applicable
• P. vivax  (100%)

See Health Information for Travelers to Greece .

Greenland (Denmark)

See Health Information for Travelers to Greenland (Denmark) .

See Health Information for Travelers to Grenada .

Guadeloupe (including Marie-Galante, La Désirade & Îles des Saintes)

See Health Information for Travelers to Guadeloupe .

Guam (U.S.)

See Health Information for Travelers to Guam (U.S.) .

• Primarily in the departments of Alta Verapaz, Escuintla, Izabal, Petén, and Suchitapéquez
• Few cases reported in other departments
• No malaria transmission in the cities of Antigua or Guatemala City (the capital)
• No malaria transmission at Lake Atitlán
• P. vivax (99%)
• P. falciparum  (1%)
• Departments of Alta Verapaz, Escuintla, Izabal, Petén, and Suchitapéquez: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine 5 , tafenoquine 3
• Other areas with reported malaria transmission: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Guatemala .

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission. 1 Required for all arriving travelers from all countries if traveler is ≥9 months of age and arriving at Ahmed Sékou Touré International Airport in Conakry.

See Health Information for Travelers to Guinea .

Guinea-Bissau

See Health Information for Travelers to Guinea-Bissau .

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes >4-hour airport transits or layovers in countries with risk for YF virus transmission. 1

• Rare cases in the cities of Georgetown (the capital) and New Amsterdam
• All areas (except the cities of Georgetown and New Amsterdam): Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• Cities of Georgetown and Amsterdam: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Guyana .

• All (including Labadee, also known as Port Labadee)
• P. falciparum (99%)
• P. malariae  (rare)
• Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Haiti .

Entry requirements : Required for travelers 1-60 years old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

• Throughout the country and on the island of Roat á n and other Bay Islands
• No malaria transmission in the cities of San Pedro Sula or Tegucigalpa (the capital)
• P. vivax (93%)
• P. falciparum  (7%)
• Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Honduras .

Hong Kong Special Administrative Region, China

See Health Information for Travelers to Hong Kong SAR (China) .

See Health Information for Travelers to Hungary .

See Health Information for Travelers to Iceland .

• Arrive within 6 days of leaving an area with risk for YF virus transmission, or
• Have been in such an area in transit (exception: passengers and members of flight crews who, while in transit through an airport in an area with risk for YF virus transmission, remained in the airport during their entire stay and the health officer agrees to such an exemption), or
• Arrive on a ship that started from or touched at any port in an area with risk for YF virus transmission ≤30 days before its arrival in India, unless such a ship has been disinsected in accordance with the procedure recommended by the World Health Organization (WHO), or
• Arrive on an aircraft that has been in an area with risk for YF virus transmission and has not been disinsected in accordance with the Indian Aircraft Public Health Rules, 1954, or as recommended by WHO.
• Africa: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Mauritania, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, South Sudan, Sudan, Togo, Uganda
• Americas: Argentina, Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Panama, Paraguay, Peru, Suriname, Trinidad & Tobago (Trinidad only), Venezuela
• Throughout the country, including the cities of Bombay (Mumbai) and New Delhi (the capital)
• No malaria transmission in areas >2,000 m (≈6,500 ft) elevation in Himachal Pradesh, Jammu and Kashmir, or Sikkim
• P. vivax (50%)
• P. falciparum (>40%)

See Health Information for Travelers to India .

• All areas of eastern Indonesia (the provinces of Maluku, North Maluku, East Nusa Tenggara, Papua, and West Papua), including the town of Labuan Bajo and the Komodo Islands in the Nusa Tenggara region
• Rural areas of Kalimantan (Borneo), West Nusa Tenggara (includes the island of Lombok), Sulawesi, and Sumatra
• Low transmission in rural areas of Java, including Pangandaran, Sukabumi, and Ujung Kulon
• No malaria transmission in the cities of Jakarta (the capital) or Ubud
• No malaria transmission in the resort areas of Bali or Java, the Gili Islands, or the Thousand Islands (Pulau Seribu)
• Chloroquine ( P. falciparum and P. vivax )
• P. falciparum (60%)
• P. vivax (40%)

See Health Information for Travelers to Indonesia .

• Previously, March-November in rural areas of Fars Province, Sistan-Baluchestan Province, and southern, tropical parts of Hormozgan and Kerman Provinces.
• Recent outbreaks in Sistan-Baluchestan Province near the border with Pakistan.
• P. vivax (90%)
• Sistan-Baluchestan Province along the border with Pakistan: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 2
• All other areas with previous transmission: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Iran .

See Health Information for Travelers to Iraq .

See Health Information for Travelers to Ireland .

See Health Information for Travelers to Israel, including the West Bank and Gaza .

Italy (including Holy See [Vatican City])

See Health Information for Travelers to Italy .

See Health Information for Travelers to Jamaica .

See Health Information for Travelers to Japan .

See Health Information for Travelers to Jordan .

Entry requirements : Required for travelers arriving from countries with risk for YF virus transmission; this includes airport transits or layovers in countries with risk for YF virus transmission. 1

See Health Information for Travelers to Kazakhstan .

CDC recommendations : Recommended for all travelers ≥9 months old except as follows. Generally not recommended for travel limited to: the city of Nairobi (the capital); the counties of the former North Eastern Province (Mandera, Wajir, and Garissa); or the counties (except Taita-Taveta) of the former Coast Province (Kilifi, including the city of Malindi; Kwale; Lamu; Mombasa, including the city of Mombasa; Tana River) .

• All areas (including game parks) <2,500 m (≈8,200 ft) elevation, including the city of Nairobi (the capital)
• Map 2-08 Yellow fever vaccine recommendations for Kenya & neighboring countries
• Map 2-09 Malaria prevention in Kenya

See Health Information for Travelers to Kenya .

Kiribati (formerly Gilbert Islands), includes Tarawa, Tabuaeran (Fanning Island), and Banaba (Ocean Island)

See Health Information for Travelers to Kiribati .

See Health Information for Travelers to Kosovo .

See Health Information for Travelers to Kuwait .

See Health Information for Travelers to Kyrgyzstan .

• All, except in Vientiane (the capital) where there is no transmission
• P. vivax (55%)
• P. falciparum (45%)
• P. knowlesi 6 , P. malariae, and P. ovale (rare)
• Areas bordering Burma (the provinces of Bokeo and Luang Namtha), Cambodia; Thailand (the provinces of Champasak and Salavan); and Vietnam: Atovaquone-proguanil, doxycycline, tafenoquine 3
• All other areas with malaria transmission: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Laos .

See Health Information for Travelers to Latvia .

See Health Information for Travelers to Lebanon .

See Health Information for Travelers to Lesotho .

See Health Information for Travelers to Liberia .

See Health Information for Travelers to Libya .

Liechtenstein

See Health Information for Travelers to Liechtenstein .

See Health Information for Travelers to Lithuania .

See Health Information for Travelers to Luxembourg .

Macau Special Administrative Region, China

See Health Information for Travelers to Macau SAR (China) .

• All; except in Antananarivo (the capital) where malaria transmission is rare
• P. ovale and P. vivax (less commonly)
• All areas (except the city of Antananarivo): Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• Antananarivo: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

See Health Information for Travelers to Madagascar .

Madeira Islands (Portugal)

See Health Information for Travelers to Madeira Islands (Portugal) .

See Health Information for Travelers to Malawi .

• No indigenous cases of human malaria since 2017
• Zoonotic transmission of simian malaria occurs in rural, forested areas
• No malaria transmission in other areas, including Kuala Lumpur (the capital), in Penang State, on Penang Island, or in George Town (capital of Penang State)
• P. knowlesi 6 (primarily)
• Previously, P. falciparum , P. malariae , P. ovale , and P. vivax
• In rural, forested areas: atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Malaysia .

See Health Information for Travelers to Maldives .

See Health Information for Travelers to Mali .

See Health Information for Travelers to Malta .

Marshall Islands

See Health Information for Travelers to Marshall Islands .

See Health Information for Travelers to Martinique (France) .

• All; except in the regions of Dakhlet Nouadhibou and Tiris Zemmour where there is no transmission

See Health Information for Travelers to Mauritania .

See Health Information for Travelers to Mauritius .

Mayotte (France)

See Health Information for Travelers to Mayotte (France) .

• Chiapas and southern part of Chihuahua state
• Rare in the states of Campeche, Durango, Nayarit, Quintana Roo, Sinaloa, Sonora, and Tabasco
• No malaria transmission along the U.S.–Mexico border
• Chiapas and southern part of Chihuahua state: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine 5 , tafenoquine 3
• All other areas with malaria transmission: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

Map 2-10 Malaria prevention in Mexico

See Health Information for Travelers to Mexico .

Micronesia, Federated States of (including Chuuk, Kosrae, Pohnpei & Yap)

See Health Information for Travelers to Micronesia, Federated States of .

See Health Information for Travelers to Moldova .

See Health Information for Travelers to Monaco .

See Health Information for Travelers to Mongolia .

See Health Information for Travelers to Montenegro .

Montserrat, United Kingdom

See Health Information for Travelers to Montserrat (U.K.) .

See Health Information for Travelers to Morocco .

See Health Information for Travelers to Mozambique .

• In the regions of Kavango (East and West), Kunene, Ohangwena, Omaheke, Omusati, Oshana, Oshikoto, Otjozondjupa, and Zambezi
• Rare in other parts of the country
• No malaria transmission in Windhoek (the capital)
• Kavango (East and West), Kunene, Ohangwena, Omaheke, Omusati, Oshana, Oshikoto, Otjozondjupa, and Zambezi: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Namibia .

See Health Information for Travelers to Nauru .

• Throughout the country in areas <2,000 m (≈6,500 ft) elevation
• No malaria transmission in Kathmandu (the capital) or on typical Himalayan treks
• P. falciparum (<10%)

See Health Information for Travelers to Nepal .

Netherlands

See Health Information for Travelers to The Netherlands .

Netherlands Antilles (Bonaire, Curaçao, Saba, St. Eustasius, and St. Maarten)

Entry requirements : See Bonaire, Curaçao, Saba, St. Eustasius, and St. Maarten for yellow fever information.

• See Bonaire, Curaçao, Saba, St. Eustasius, and St. Maarten for malaria information.

New Caledonia (France)

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1 In the event of an epidemic threat to the territory, a specific vaccination certificate may be required.

See Health Information for Travelers to New Caledonia (France) .

New Zealand

See Health Information for Travelers to New Zealand .

• Región Autónoma Atlántico Norte (RAAN) and Región Autónoma Atlántico Sur (RAAS)
• Rare cases in the departments of Boaco, Chinandega, Estelí, Jinotega, León, Matagalpa, and Nueva Segovia
• No malaria transmission in Managua (the capital)
• P. falciparum  (20%)
• Región Autónoma Atlántico Norte (RAAN) and Región Autónoma Atlántico Sur (RAAS): Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, tafenoquine 3

See Health Information for Travelers to Nicaragua .

See Health Information for Travelers to Niger .

CDC recommendations : Recommended for all travelers ≥9 months old.  

See Health Information for Travelers to Nigeria .

Niue (New Zealand)

See Health Information for Travelers to Niue (New Zealand) .

Norfolk Island (Australia)

See Health Information for Travelers to Norfolk Island (Australia) .

North Korea

• Southern provinces
• P. vivax (100%)
• Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine 5 , tafenoquine 3

See Health Information for Travelers to North Korea .

North Macedonia

See Health Information for Travelers to North Macedonia .

Northern Mariana Islands (U.S.), includes Saipan, Tinian, and Rota Island

See Health Information for Travelers to Northern Mariana Islands (U.S.) .

See Health Information for Travelers to Norway .

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission, with the addition of Rwanda and Tanzania; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

• Rare sporadic transmission after importation only
• Previously, P. falciparum and P. vivax

See Health Information for Travelers to Oman .

• All areas (including all cities) <2,500 m (≈8,200 ft) elevation

See Health Information for Travelers to Pakistan .

See Health Information for Travelers to Palau .

CDC recommendations : Recommended for travelers ≥9 months old going to all mainland areas east of the Canal Zone including Darién Province, the indigenous provinces (comarcas indígena) of Emberá and Kuna Yala (also spelled Guna Yala), and areas of the provinces of Colón and Panamá, east of the Canal Zone. Not recommended for travel limited to the Canal Zone; areas west of the Canal Zone; Panama City (the capital); Balboa district (Pearl Islands) of Panamá Province; or the San Blas Islands of Kuna Yala Province.

• The provinces of Bocas del Toro, Chiriquí, Colón, Darién, Panamá, and Veraguas
• The indigenous provinces (comarcas indígena) of Emberá, Kuna Yala (also spelled Guna Yala) and Ngäbe-Buglé
• No malaria transmission in the province of Panamá Oeste, in the Canal Zone, or in Panama City (the capital)
• Chloroquine (east of the Panama Canal)
• P. vivax (97%)
• P. falciparum  (3%)
• Darién, Emberá, Kuna Yala, and eastern Panamá Provinces : Atovaquone-proguanil, doxycycline, mefloquine, primaquine 5 , tafenoquine 3
• Bocas del Toro, Chiriquí, Colón, Veraguas, and Ngäbe-Buglé Provinces : Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine 5 , tafenoquine 3
• Map 2-11 Yellow fever vaccine recommendations for Panama & neighboring countries
• Map 2-12 Malaria prevention in Panama

See Health Information for Travelers to Panama .

Papua New Guinea

• Chloroquine (both P. falciparum and P. vivax )
• P. falciparum (75%)
• P. vivax (25%)

See Health Information for Travelers to Papua New Guinea .

Entry requirements : Required for travelers ≥1 year old arriving from Bolivia, Brazil, Peru, or Venezuela; this includes this includes >24-hour transits or layovers in those countries 1

CDC recommendations : Recommended for all travelers ≥9 months old except as follows. Generally not recommended for travel limited to the city of Asunción (the capital).

See Health Information for Travelers to Paraguay .

CDC recommendations : Recommended for travelers ≥9 months old going to areas <2,300 m (≈7,550 ft) elevation in the regions of Amazonas, Cusco, Huánuco, Junín, Loreto, Madre de Dios, Pasco, Puno, San Martín, and Ucayali, and designated areas of Ancash (far northeast), Apurímac (far north), Ayacucho (north and northeast), Cajamarca (north and east), Huancavelica (far north), La Libertad (east), and Piura (east). Generally not recommended for travel limited to the following areas west of the Andes: the regions of Lambayeque and Tumbes, and designated areas of Cajamarca (west-central), and Piura (west). Not recommended for travel limited to areas >2,300 m (≈7,550 ft) elevation, areas west of the Andes not listed above, the city of Lima (the capital), and the highland tourist areas (the city of Cusco, the Inca Trail, and Machu Picchu).

• All areas of the country <2,500 m (≈8,200 ft) elevation, including the cities of Iquitos and Puerto Maldonado, and only the remote eastern areas in the regions of La Libertad and Lambayeque
• No malaria transmission in the following areas: Lima Province; the cities of Arequipa, Ica, Moquegua, Nazca, Puno, or Tacna; the highland tourist areas (the city of Cusco, Machu Picchu, Lake Titicaca); along the Pacific Coast
• Map 2-13 Yellow fever vaccine recommendations for Peru & neighboring countries
• Map 2-14 Malaria prevention in Peru

See Health Information for Travelers to Peru .

Philippines

• Palawan and Mindanao Islands
• No malaria transmission in metropolitan Manila (the capital) or other urban areas
• P. falciparum (85%)
• P. vivax (15%)

See Health Information for Travelers to Philippines .

Pitcairn Islands (U.K.)

See Health Information for Travelers to Pitcairn Islands (U.K.) .

See Health Information for Travelers to Poland .

See Health Information for Travelers to Portugal .

Puerto Rico (U.S.)

See Health Information for Travelers to Puerto Rico (U.S.) .

See Health Information for Travelers to Qatar .

Réunion (France)

See Health Information for Travelers to Réunion (France) .

See Health Information for Travelers to Romania .

See Health Information for Travelers to Russia .

CDC recommendations : Generally not recommended for travel to Rwanda.

See Health Information for Travelers to Rwanda .

Saba, Netherlands

See Health Information for Travelers to Saba .

Saint Barthelemy, France

Saint helena, united kingdom.

Entry requirements : Required for travelers ≥1 year old arriving from countries with risk for YF virus transmission. 1 *For YF vaccine entry requirements and recommendations and malaria prevention information for Ascension Island and Tristan da Cunha archipelago, see: UNITED KINGDOM (including CHANNEL ISLANDS, ISLE OF MAN, ASCENSION ISLAND & TRISTAN DA CUNHA ARCHIPELAGO)

See Health Information for Travelers to Saint Helena (U.K.) .

Saint Kitts (Saint Christopher) & Nevis

See Health Information for Travelers to Saint Kitts and Nevis .

Saint Lucia

See Health Information for Travelers to Saint Lucia .

Saint Martin, France

Saint pierre and miquelon (france).

See Health Information for Travelers to Saint Pierre and Miquelon (France) .

Saint Vincent and the Grenadines

See Health Information for Travelers to Saint Vincent and the Grenadines .

Samoa (formerly Western Somoa)

See Health Information for Travelers to Samoa (formerly Western Samoa) .

See Health Information for Travelers to San Marino .

São Tomé and Príncipe

CDC recommendations : Generally not recommended for travel to São Tomé and Príncipe.

See Health Information for Travelers to São Tomé and Príncipe.

Saudi Arabia

• Asir and Jazan (also spelled Jizan) Regions near the Yemen border only
• No malaria transmission in the cities of Jeddah, Mecca, Medina, Riyadh (the capital), or Ta’if
• P. vivax (rare)

See Health Information for Travelers to Saudi Arabia .

See Health Information for Travelers to Senegal .

See Health Information for Travelers to Serbia .

See Health Information for Travelers to Seychelles .

Sierra Leone

Entry requirements : Required for all arriving travelers.

See Health Information for Travelers to Sierra Leone .

See Health Information for Travelers to Singapore .

Sint Eustatius, Netherlands

Entry requirements : Required for travelers ≥6 months old arriving from countries with risk for YF virus transmission. 1

See Health Information for Travelers to Sint Eustatius .

Sint Maarten, Netherlands

See Health Information for Travelers to Sint Maarten .

See Health Information for Travelers to Slovakia .

See Health Information for Travelers to Slovenia .

Solomon Islands

• P. vivax (70%)
• P. falciparum (30%)
• P. ovale (<1%)

See Health Information for Travelers to Solomon Islands .

CDC recommendations : Generally not recommended for travel to the regions of Bakool, Banaadir, Bay, Galguduud, Gedo, Hiiraan (also spelled Hiran), Lower Juba (also known as Jubbada Hoose), Middle Juba (also known as Jubbada Dhexe), Lower Shabelle (also known as Shabeellaha Hoose), or Middle Shabelle (also known as Shabeellaha Dhexe). Not recommended for travel to areas not listed above.

• P. vivax (5–10%)

See Health Information for Travelers to Somalia .

South Africa

• Along the border with Mozambique and Zimbabwe
• KwaZulu-Natal Province: uMkhanyakude District; the districts of King Cetshwayo and Zululand (few cases) Limpopo Province: the districts of Mopani and Vhembe; the districts of Capricorn, Greater Sekhukhune, and Waterberg (few cases)
• Mpumalanga Province: Ehlanzeni District
• Kruger National Park
• KwaZulu-Natal Province (uMkhanyakude District); Limpopo Province (the districts of Mopani and Vhembe); Mpumalanga Province (Ehlanzeni District); and Kruger National Park: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• All other areas with malaria transmission (including the districts of King Cetshwayo and Zululand in KwaZulu-Natal Province, and the districts of Capricorn, Greater Sekhukhune, and Waterberg in Limpopo Province): No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

Map 2-15 Malaria prevention in South Africa

See Health Information for Travelers to South Africa .

South Georgia & the South Sandwich Islands, UK Overseas Territory (also claimed by Argentina)

Entry requirements : South Georgia & the South Sandwich Islands has not stated its YF vaccination certificate requirements.

See Health Information for Travelers to South Georgia and the South Sandwich Islands (U.K.) .

South Korea

Entry requirements : Required if traveling from a country with risk of YF virus transmission and ≥1 year of age. 1

• Limited to the months of March– December in rural areas in the northern parts of the provinces of Inch’ŏn (also spelled Incheon), Kangwŏn (also spelled Gangwon), and Kyŏnggi (also spelled Gyeonggi), including the demilitarized zone (DMZ)
• Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine 5 , or tafenoquine 3

See Health Information for Travelers to South Korea .

South Sudan

See Health Information for Travelers to South Sudan .

See Health Information for Travelers to Spain .

See Health Information for Travelers to Sri Lanka .

CDC recommendations : Recommended for travelers ≥9 months old going to areas south of the Sahara Desert. Not recommended for travel limited to areas in the Sahara Desert or the city of Khartoum (the capital).

See Health Information for Travelers to Sudan .

• Primarily in Sipaliwini District, near the border with French Guiana
• Limited transmission in Brokopondo, Marowijne, and Para (near the border with French Guiana)
• No malaria transmission in the districts along the Atlantic Coast or in Paramaribo (the capital)
• Sipaliwini District near the border with French Guiana: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• All other areas with malaria transmission: No chemoprophylaxis recommended (insect bite precautions / mosquito avoidance only) 4

See Health Information for Travelers to Suriname .

See Health Information for Travelers to Sweden .

Switzerland

See Health Information for Travelers to Switzerland .

See Health Information for Travelers to Syria .

See Health Information for Travelers to Taiwan .

• No indigenous cases reported since 2014
• Previously, P. vivax (90%)
• Previously, P. falciparum  (10%)

See Health Information for Travelers to Tajikistan .

CDC recommendations : Generally not recommended for travel to Tanzania.

• All areas below 1,800 m (≈5,900 ft) elevation
• P. malariae and P. ovale (less commonly)

See Health Information for Travelers to Tanzania .

• Primarily the provinces that border Burma, Cambodia (few cases in Buri Ram Province), and Malaysia (few cases in Satun Province) Also, the provinces of Phitsanulok and Ubon Ratchathani (bordering Laos), and Surat Thani (especially in the rural forest and forest-fringe areas of these provinces)
• Rare to few cases in other parts of Thailand, including the cities of Bangkok (the capital), Chiang Mai, and Chiang Rai, or on the islands of Koh Pha Ngan, Koh Samui, or Phuket
• No malaria transmission on the islands of Krabi Province (Ko Lanta, Koh Phi, Koh Yao Noi, Koh Yao Yai) or in Pattaya City
• P. falciparum (<20%)
• Provinces that border Burma, Cambodia (except Buri Ram Province), and Malaysia (except Satun Province); the provinces of Phitsanulok, Ubon Ratchathani, and Surat Thani: Atovaquone-proguanil, doxycycline, tafenoquine 3
• All other areas with malaria transmission (including the provinces of Buri Ram and Satun): No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

Map 2-16 Malaria prevention in Thailand

See Health Information for Travelers to Thailand .

Timor-Leste

• Rare cases; outbreak in Indonesia border area in mid-2020
• Previously, P. falciparum (50%)
• Previously, P. vivax (50%)
• Previously, P. malariae  and  P. ovale  (each <1%)

See Health Information for Travelers to Timor-Leste (East Timor) .

See Health Information for Travelers to Togo .

Tokelau (New Zealand)

See Health Information for Travelers to Tokelau (New Zealand) .

See Health Information for Travelers to Tonga .

Trinidad and Tobago

CDC recommendations : Recommended for travelers ≥9 months old going to densely forested areas on Trinidad. Not recommended for cruise ship passengers, airplane passengers in transit, or travel limited to Tobago.

See Health Information for Travelers to Trinidad and Tobago .

See Health Information for Travelers to Tunisia .

See Health Information for Travelers to Turkey .

Turkmenistan

See Health Information for Travelers to Turkmenistan .

Turks and Caicos Islands (U.K.)

See Health Information for Travelers to Turks and Caicos Islands (U.K.) .

See Health Information for Travelers to Tuvalu .

See Health Information for Travelers to Uganda .

See Health Information for Travelers to Ukraine .

United Arab Emirates

See Health Information for Travelers to United Arab Emirates .

United Kingdom (including Channel Islands, Isle of Man, Ascension Island & Tristan Da Cunha Archipelago)

See Health Information for Travelers to United Kingdom .

United States of America

See Health Information for Travelers to United States .

See Health Information for Travelers to Uruguay .

See Health Information for Travelers to Uzbekistan .

• P. vivax (75%–90%)
• P. falciparum (10-25%)

See Health Information for Travelers to Vanuatu .

Entry requirements : Required for travelers ≥1 year old arriving from Brazil; this includes >12-hour airport transits or layovers in Brazil

CDC recommendations : Recommended for all travelers ≥9 months old except as follows. Generally not recommended for travel limited to the Distrito Capital or the states of Aragua, Carabobo, Miranda, Vargas, or Yaracuy. Not recommended for travel limited to areas >2,300m (≈7,550 ft) elevation in the states of Mérida, Táchira, or Trujillo; the states of Falcón or Lara; Margarita Island; or the cities of Caracas (the capital) or Valencia .

• All areas <1,700 m (≈5,600 ft) elevation and Angel Falls
• P. vivax (75%)
• P. falciparum  (25%)

Map 2-17 Yellow fever vaccine recommendations for Venezuela & neighboring countries

See Health Information for Travelers to Venezuela .

• Rural areas only. Rare cases in the Mekong and Red River Deltas
• None in the cities of Da Nang, Hai Phong, Hanoi, Ho Chi Minh City (Saigon), Nha Trang, and Quy Nhon.
• P. falciparum (65%)
• P. vivax (35%)
• Provinces of Bình Dương, Bình Phước, Đắk Lắk, Đắk Nông, Gia Lai, Khánh Hòa, Kon Tum, Lâm Đồng, Ninh Thuận, Tây Ninh: Atovaquone-proguanil, doxycycline, tafenoquine 3
• All other areas with malaria transmission (except Mekong and Red River Deltas): Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine 3
• Mekong and Red River Deltas: No chemoprophylaxis recommended (insect bite precautions / mosquito avoidance only) 4

See Health Information for Travelers to Vietnam .

Virgin Islands, British

See Health Information for Travelers to Virgin Islands, British .

Virgin Islands, U.S.

See Health Information for Travelers to Virgin Islands, U.S. .

Wake Island, U.S.

See Health Information for Travelers to Wake Island .

• All areas <2,000 m (≈6,500 ft) elevation
• No malaria transmission in Sana’a (the capital)

See Health Information for Travelers to Yemen .

Entry requirements : Required for travelers ≥1 year of age arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

CDC recommendations : Generally not recommended for travel to North-Western Province or Western Province. Not recommended for travel to any areas not listed above.

See Health Information for Travelers to Zambia .

See Health Information for Travelers to Zimbabwe .

1 Current as of November 2022. This is an update of the 2010 map created by the Informal WHO Working Group on the Geographic Risk of Yellow Fever.

2 Refers to Plasmodium falciparum malaria, unless otherwise noted.

3 Tafenoquine can cause potentially life-threatening hemolysis in people with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. Rule out G6PD deficiency with a quantitative laboratory test before prescribing tafenoquine to patients.

4 Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide-treated mosquito net, and wearing protective clothing (e.g., long pants and socks, long-sleeve shirt). For additional details on insect bite precautions, see Sec. 4, Ch. 6, Mosquitoes, Ticks & Other Arthropods.

5 Primaquine can cause potentially life-threatening hemolysis in people with G6PD deficiency. Rule out G6PD deficiency with a quantitative laboratory test before prescribing primaquine to patients.

6 P. knowlesi is a malaria species with a simian (macaque) host. Human cases have been reported from most countries in Southwest Asia and are associated with activities in forest or forest-fringe areas. P. knowlesi has no known resistance to antimalarials.

Yellow Fever Maps

2 In 2017, the Centers for Disease Control and Prevention (CDC) expanded its YF vaccination recommendations for travelers going to Brazil because of a large YF outbreak in multiple states in that country. Please refer to the CDC  Travelers’ Health website for more information and updated recommendations.

3 YF vaccination is generally not recommended for travel to areas where the potential for YF virus exposure is low. Vaccination might be considered, however, for a small subset of travelers going to these areas who are at increased risk for exposure to YF virus due to prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Factors to consider when deciding whether to vaccinate a traveler include destination-specific and travel-associated risks for YF virus infection; individual, underlying risk factors for having a serious YF vaccine–associated adverse event; and destination entry requirements.

The following authors contributed to the previous version of this chapter: Mark D. Gershman, Emily S. Jentes, Rhett J. Stoney (Yellow Fever) Kathrine R. Tan, Paul M. Arguin (Malaria)

File Formats Help:

• Adobe PDF file
• Microsoft PowerPoint file
• Microsoft Word file
• Microsoft Excel file
• Audio/Video file
• Apple Quicktime file
• RealPlayer file
• Zip Archive file

• Turistička agencija Trend Travel DMC Herceg Novi
• +382 69 570 027
• +381 649 276 352
• [email protected]

Zimsko radno vrijeme

Agencija u Starom gradu Svakoga dana 08:00 - 20:00

Ekspozitura preko puta Glavne Autobuske Stanice Herceg Novi Svakoga dana 07:00 - 21:00

Ljetnje radno vrijeme

Agencija u Starom gradu Svakoga dana 07:00 - 23:00

Ekspozitura preko puta Glavne Autobuske Stanice Herceg Novi Svakoga dana 07:00 - 23:00

Inspiracija za putovanje

Ukoliko Vam nikada nije dosta putovanja, pratite nas na društvenim mrežama i na taj način budite u toku sa najnovijim dešavanjima iz sveta turizma.

Kontaktirajte nas, rado ćemo odgovoriti.

Ime i prezime Email Telefon Tekst poruke

Trend Travel DMC Herceg Novi

Lokacija Trg Hercega Stjepana 4, Herceg Novi, Crna Gora

Email ​ [email protected]

If you see this Google Maps wasn't properly loaded. Please refresh your page :)

Trend Travel DMC Ekspozitura preko puta Glavne Autobuske Stanice Herceg Novi

Lokacija Ul. Orijenski bataljon 3, Herceg Novi, Crna Gora

Email ​ ​ [email protected]